尚榮醫療(002551.SZ):尚榮醫院後勤擬對富平醫管增資2億元
格隆匯11月25日丨尚榮醫療(002551.SZ)公佈,富平醫管為公司全資子公司尚榮醫療投資的控股子公司,尚榮醫療投資持有其 52.017%股權,尚榮醫療投資擬將持有富平醫管52.017%股權轉讓給公司全資子公司尚榮醫院後勤,轉讓價格為7417.99萬元。本次股權轉讓完成後,尚榮醫院後勤將持有富平醫管52.017%股權。
為補充醫院運營資金及償還醫院債務,以降低財務費用,提高醫院運營效率,公司於2021年11月25日召開第七屆董事會第二次臨時會議,審會議以9票贊成、0票棄權、0票反對的表決結果審議通過了《關於全資子公司對控股孫公司增資的議案》。同意公司全資子公司尚榮醫院後勤擬使用自有資金以現金方式按照其註冊資本為依據對控股孫公司富平醫管增加註冊資本2億元。增資完成後富平醫管註冊資本為3.6億元,尚榮醫院後勤持有其78.674%股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.